Legend Biotech Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Legend Biotech stock has a consensus rating of "Buy" and an average price target of $45.62. The average 1-year stock price forecast is 141.38% higher than the current stock price, while the lowest is $24 (+26.98%) and the highest is $68 (+259.79%).

Price Target: $45.62 (+141.38%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$24	$45.62	$48	$68
Change	+26.98%	+141.38%	+153.97%	+259.79%

Analyst Ratings

The average analyst rating for Legend Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	8	7	6	5	3	3
Buy	5	5	5	5	5	5
Hold	2	2	4	5	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	14	15	15	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $65	Buy	Reiterates	$65	+243.92%	Oct 19, 2026
Ziyi Chen Goldman Sachs	Goldman Sachs	Buy Maintains $39 → $38	Buy	Maintains	$39 → $38	+101.53%	Oct 14, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $74 → $68	Buy	Maintains	$74 → $68	+259.79%	Oct 13, 2026
Jessica Fye J.P. Morgan	J.P. Morgan	Hold Maintains $35 → $33	Hold	Maintains	$35 → $33	+74.60%	Oct 9, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $58 → $56	Buy	Maintains	$58 → $56	+196.30%	Oct 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.44B

from 1.03B

39.73%

from 1.03B

Revenue Next Year

1.77B

from 1.44B

23.42%

from 1.44B

EPS This Year

-0.01

from -1.60

EPS Next Year

1.05

from -0.01

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	68.83M	117.01M	285.10M	627.30M	1.03B	1.44B
Revenue Growth	-8.23%	70.00%	143.67%	120.03%	64.02%	39.73%
Gross Profit	68.83M	51.64M	140.90M	392.70M	620.80M	802.84M
Gross Margin	100.00%	44.14%	49.42%	62.60%	60.34%	55.84%
Operating Income	-394.02M	-458.05M	-528.10M	-305.10M	-136.50M	12.76M
Net Income	-403.58M	-446.35M	-518.30M	-177.00M	-296.80M	-12.18M
EPS	-	-	-	-	-1.60	-0.01
Free Cash Flow	-	-	-	-	-128.80M	44.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.5B
Avg	1.4B
Low	1.4B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	43.2%
Avg	39.7%
Low	37.2%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.01
Avg	-0.01
Low	-0.01

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-